Omalizumab retreatment in patients with chronic spontaneous urticaria: a systematic review of published evidence.

Omalizumab retreatment in patients with chronic spontaneous urticaria: a systematic review of published evidence.
Eur Ann Allergy Clin Immunol. 2020 Feb 28;:
Authors: Tonacci A, Nettis E, Asero R, Rossi O, Tontini C, Gangemi S
Abstract
Summary: A systematic review of the current literature on retreatment with omalizumab of patients with relapsing chronic spontaneous urticaria was performed. Published evidence shows that retreatment is safe and clinically effective, and that time to complete clinical response reduces as the number of retreatments increases.
PMID: 32108461 [PubMed - as supplied by publisher]

Source: European Annals of Allergy and Clinical Immunology - March 1, 2020 Category: Allergy & Immunology Tags: Eur Ann Allergy Clin Immunol Source Type: research